Drawing for M

USPTO serial 88373425

M

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
HELMERS, SARA A
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with M?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Matthew J. Clark

Matthew J. Clark FROST BROWN TODD LLCSUITE 1900201 NORTH ILLINOIS STREETINDIANAPOLIS, IN 46204

Goods and services

ClassDescriptionStatusFirst use
005Cohesive bandages for dressings and skin wounds; Medical diagnostic test strips, namely, urinalysis test strips; Pharmaceuticals for the treatment of medical conditions, namely, prescription pharmaceutical products, oral pharmaceuticals, and topical pharmaceuticals for the treatment of infectious diseases; Pharmaceuticals for the treatment of medical conditions, namely, prescription pharmaceutical products, oral pharmaceuticals, and topical pharmaceuticals for the treatment of skin diseases and conditions, namely, eczema, dermatitis, lupus, psoriasis, skin aging, wrinkles, melanoma, aesthetic enhancements, hives, impetigo, rosacea, moles, skin cancer, wound healing, scar revision, dehydration and nutritional deficiency, and internal diseases and conditions, namely, dehydration, nutritional deficiency, cancer, liver disease, kidney disease, diabetes, pneumonia, hypothyroidism, hyperthyroidism, arterial sclerosis, anxiety, ADHD, autism, and asthma; Pharmaceuticals for the treatment of medical conditions, namely, non-prescription pharmaceutical products, oral pharmaceuticals, and topical pharmaceuticals for the treatment of infectious diseases; Pharmaceuticals for the treatment of medical conditions, namely, non-prescription pharmaceutical products, oral pharmaceuticals, and topical pharmaceuticals for the treatment of skin diseases and conditions, namely, eczema, dermatitis, lupus, psoriasis, skin aging, wrinkles, melanoma, aesthetic enhancements, hives, impetigo, rosacea, moles, skin cancer, wound healing, scar revision, dehydration and nutritional deficiency, and internal diseases and conditions, namely, dehydration and nutritional deficiency; Anesthetics; Nutritional supplements; Dietary supplements; Vitamins; Adhesive strips for medical purposes; Containers for enteral solutions sold pre-filled with feeding formulas; Containers for parenteral solutions sold pre-filled with feeding formulasACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Feb 14, 2022MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Feb 14, 2022ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Oct 6, 2021NOACCORRECTED NOA E-MAILED—
Oct 5, 2021DPCCDIVISIONAL PROCESSING COMPLETE—
Sep 22, 2021AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Sep 15, 2021DRRRDIVISIONAL REQUEST RECEIVED—
Sep 15, 2021ERTDTEAS REQUEST TO DIVIDE RECEIVED—
Jul 14, 2021EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jul 12, 2021EX2GSOU EXTENSION 2 GRANTED—
Jul 12, 2021EXT2SOU EXTENSION 2 FILED—
Jul 12, 2021EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jan 16, 2021EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jan 14, 2021EX1GSOU EXTENSION 1 GRANTED—
Jan 14, 2021EXT1SOU EXTENSION 1 FILED—
Jan 14, 2021EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jul 14, 2020NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
May 19, 2020NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
May 19, 2020PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Apr 29, 2020NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Apr 10, 2020CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Apr 1, 2020TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Mar 31, 2020CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Mar 31, 2020ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
Jan 30, 2020RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Jan 13, 2020ALIEASSIGNED TO LIE—
Jun 19, 2019GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Jun 19, 2019GNSLLETTER OF SUSPENSION E-MAILED—
Jun 19, 2019CNSLSUSPENSION LETTER WRITTEN—
Jun 17, 2019DOCKASSIGNED TO EXAMINER—
Apr 25, 2019MDSMNOTICE OF DESIGN SEARCH CODE E-MAILED—
Apr 23, 2019NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 9, 2019NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance